[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bmd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bmd":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100447167","swiss-registry-for-neuromuscular-disorders-100447167",false,"NCT05102916","Swiss Registry for Neuromuscular Disorders","Swiss Registry for Neuromuscular Disorders (Swiss-Reg-NMD)","Swiss-Reg-NMD","Inclusion Criteria:\n\n* Children, adolescents and adults diagnosed with a NMD\n* Who are living or treated for a NMD in Switzerland, and\n* Who gave informed consent\n\nExclusion Criteria:\n\n* None if diagnosis is confirmed, whenever possible, by genetic testing, or at least by biopsy and\u002For electroneuromyography, according to international standards for the diagnosis of the given NMD.","ALL","0 Years",{"count":20,"type":21},2000,"ESTIMATED","80 Years","OBSERVATIONAL","The Swiss Patient Registry for DMD\u002FBMD and SMA was launched in 2008 in order to give Swiss patients access to new therapies. It was founded with the financial support of several patient organizations and research foundations. Since 2008, children, adolescents and adults with DMD, BMD and SMA are registered with the help of all major muscle centers in Switzerland. After nearly ten years of activity, the Swiss Patient Registry for DMD\u002FBMD and SMA implemented several adaptations in 2018 to meet current and future expectations of patient's organizations, health authorities and research organizations.",[26,27,28,29,30],"SMA","DMD","BMD","IMD","Congenital Muscular Dystrophy",[27,28,29,26,32,33,34,35],"LAMA2","COL-6","CMD","NMD","RECRUITING","2026-01-13",{"date":39,"type":40},"2026-01-15","ACTUAL",{"date":42,"type":40},"2018-06-20",{"date":44,"type":21},"2071-01-01",{"name":46,"class":47},"University of Bern","OTHER",19,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100560802","defining-outcome-measures-for-behavioural-and-emotional-problems-in-dystrophinopathies-100560802","NCT06581887","Defining Outcome Measures for Behavioural and Emotional Problems in Dystrophinopathies","D-BRAIN","Inclusion Criteria:\n\n* DMD patients:\n\n  1. Male\n  2. Age range 7-17 years\n  3. A genetically proven diagnosis of DMD.\n  4. A genetic mutation that abrogates expression of Dp427 alone (assigned in DMD Group 1: Dp427-\u002FDp140+) or both Dp427 and Dp140 (assigned to DMD Group 2: Dp427-\u002FDp140-).\n  5. Ability to consent\u002Fassent\n\nBMD patients:\n\n1. Male\n2. Age range 7-17 years\n3. A genetically proven diagnosis of BMD.\n4. A genetic mutation that decreases expression of Dp427 alone (assigned to BMD Group 1), of both Dp427 and Dp140 (assigned to BMD Group 2).\n5. Ability to consent\u002Fassent\n\nControl participants:\n\n1. Male\n2. Age range 7-17 years.\n3. Ability to consent\u002Fassent\n\nExclusion Criteria:\n\n* DMD \\& BMD patients:\n\n  1. Significant visual or hearing impairment\n  2. Specific phobias or sensory sensitivities to stimuli similar to the ones used in this study\n  3. Current participation in a clinical trial investigating a new drug involved in dystrophin modulation.\n  4. Inability to consent (for parents\u002Fguardians or self-reporting participants aged 16 and 17) or assent. This will exclude the rare individuals with extremely severe learning disability, as the assent in these patients is impossible (or the consent in self-reporting participants aged 16 and 17).\n\nControl participants:\n\n1. Significant visual or hearing impairment\n2. Specific phobias or sensory sensitivities to stimuli similar to the ones used in this study\n3. Any diagnosis of neurological or psychiatric condition\n\nGeneral exclusion criteria for MRI:\n\n1. Claustrophobia\n2. Pacemakers and defibrillators\n3. Nerve stimulators\n4. Intracranial clips\n5. Intraorbital or intraocular metallic fragments\n6. Cochlear implants\n7. Ferromagnetic implants (e.g. thoracic implant for scoliosis)\n8. Inability to lie supine during less than 45 minutes\n9. Not having a general practitioner\n10. Severe learning disability which will require a general anaesthetic",true,"MALE","7 Years","17 Years",{"count":61,"type":21},100,"Study aims to develop and to evaluate the neurophysiological and physiological response to a classical conditioning task.To better understand how Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) impacts mental health and how to assess it. Participants invited to complete questionnaires about behaviour, cognitive function and social interactions, complete computer tasks and have an optional MRI brain scan,",[27,28],[65],"Antisense oligonucleotide","2024-08-29",{"date":68,"type":40},"2024-09-03",{"date":70,"type":40},"2022-09-13",{"date":72,"type":21},"2024-12-31",{"name":74,"class":47},"University College, London",1]